| abstract |
The present invention relates to a modified α-helical bundle cytokine having reduced activity through α-helical bundle cytokine receptors, wherein said α-helical bundle cytokine is specifically delivered to the target cell. Preferably, said alpha-helical bundle cytokine is a mutant, more preferably said alpha-helical bundle cytokine is a mutant interferon having a low affinity for an interferon receptor, wherein said mutant interferon is specifically . Targeting is accomplished by fusing a modified a-helical bundle cytokine to a targeting moiety, preferably an antibody. The invention also relates to the use of said targeted modified a-helical bundle cytokines for the treatment of diseases. A preferred embodiment is the use of a targeted mutant interferon for the treatment of diseases, preferably viral diseases and tumors. |